Pharmacology & Therapeutics

Papers
(The H4-Index of Pharmacology & Therapeutics is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Editorial Board326
Potential neonatal toxicity of new psychoactive substances321
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications282
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis259
Endothelial dysfunction as a complication of anti-cancer therapy239
Inflammation, lipids, and pain in vulvar disease219
Adenosine receptor signalling as a driver of pulmonary fibrosis214
Non-canonical G protein signaling185
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption184
In cancer, all roads lead to NADPH183
Exploiting the obesity-associated immune microenvironment for cancer therapeutics173
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue164
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments162
Matrikines in the skin: Origin, effects, and therapeutic potential139
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy137
Collateral lethality: A unique type of synthetic lethality in cancers136
Unfolded protein responses: Dynamic machinery in wound healing135
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis131
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy125
The role of macrophages in asthma-related fibrosis and remodelling125
Management of drug-resistant hypertension as a heterogeneous disorder123
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance117
Cell-based therapies for vascular regeneration: Past, present and future110
TLR4 biased small molecule modulators106
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved105
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics103
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases98
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches98
Boron in cancer therapeutics: An overview97
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?97
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions95
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond91
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression91
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets90
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases89
Contribution of non-selective membrane channels and receptors in epilepsy88
TAAR1 as an emerging target for the treatment of psychiatric disorders86
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization86
Dysregulation of metabolic pathways in pulmonary fibrosis86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives86
Editorial Board84
Wnt signaling: A prospective therapeutic target for chronic pain84
Review: Sex-related differences in the treatment of cardiac arrhythmia83
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents83
Bispecific antibodies for the treatment of neuroblastoma79
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain77
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease75
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance74
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors73
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy73
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]72
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression72
PGRMC1: An enigmatic heme-binding protein72
Natural products that alleviate depression: The putative role of autophagy71
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)71
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections70
Pharmacological treatment of cardiogenic shock – A state of the art review70
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response68
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer67
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy66
DNA methylation in cell plasticity and malignant transformation in liver diseases66
Stabilizing the neural barrier – A novel approach in pain therapy63
Advances in pathogenesis and therapeutic strategies for osteoporosis63
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases63
0.78122115135193